Authors
Latest:
ViiV Healthcare Presents Potential Long-Acting HIV TherapiesPhase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.
Latest:
The Role of Pharmacists in the World of Pediatric Antimicrobial StewardshipThe limitation in the number of pediatric-specific guidelines by professional organizations, and results from large randomized clinical trials, may place an additional emphasis on literature evaluation skills for pediatric ASP pharmacists.
Latest:
Advice for Physicians to Manage C. Difficile Infection (CDI)Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
Latest:
Identifying Invasive Pneumococci in Pediatric Infections Utilizing Whole Genome SequencingThis method represents a significant advancement in case management for this population. In our latest From Pathogen to Infectious Disease Diagnosis Podcast, Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, provides insights on its capabilities and how it can potentially aid clinicians in reducing antimicrobial resistance.
Latest:
Reducing Long COVID Symptoms by Way of VaccinationResearch finds that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.
Latest:
What We Know But Still Have to Learn About Long COVIDDespite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
Latest:
Exploring the Recently Approved and Upcoming Clostridioides difficile TherapeuticsThis market has seen a flurry of activity, as shown by a review of the latest agents.
Latest:
COVID-19 Convalescent Plasma: What Is Its Role in Therapy?The key is using the right dose on the right patient at the right time.
Latest:
INSTIs and Cardiovascular Outcomes: More ComplexityThe significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Latest:
Treating Persistent Methicillin-susceptible Staphylococcus aureus (MSSA) BacteremiaEmerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).
Latest:
A Review of the Currently Available Monoclonal Antibodies for COVID-19Outside of vaccines, these underutilized therapies are the best defense against severe disease.
Latest:
Capvaxive’s EU Approval and Impact on Pneumococcal Disease Prevention: A Focus on At-Risk PopulationsHeather Platt, MD, discusses Merck’s ongoing research into real-world effectiveness and cost-effectiveness and offers a preview of data to be presented at ESCMID 2025.
Latest:
Vancomycin AUC Implementation in Resource-Limited Settings and its Associated DifficultiesThe latest article from SIDP illustrates the challenges of area under the curve (AUC) implementation and offers insights for strategies and resources to overcome them.
Latest:
Gilead's Once Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 StudyNew pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention
Latest:
Now is Not the Time for Funding Pauses, Cutting Ties With Health OrganizationsBiocontainment, including the most recent threat of highly pathogenic avian influenza, demands we continue to finance research, and continue cooperation with important organizations like the WHO.
Latest:
Opposing Forces During COVID-19: Perspective From the ICUConflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Latest:
Community-Acquired Candida Glabrata Empyema: An Atypical Diagnosis Not to MissAlthough this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
Latest:
GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis BCombining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.
Latest:
COVID-19 Booster Shots and the FutureKey opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Latest:
Oral Carbapenems: Promise, Peril, and PushbacksHere is a review of the literature for this class of antibiotics.
Latest:
What’s New With Non–COVID-19 VaccinesAlthough COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
Latest:
Lessons in Resilience: What HIV Teaches Us About COVID-19Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
Latest:
Still Learning: Optimizing the Diagnosis and Screening of Respiratory VirusesWhile the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.
Latest:
Antimicrobial Stewardship: More Is BetterA robust stewardship program requires a comprehensive investment in technology and staff.
Latest:
SHARE the Responsibility of Antibiotic Stewardship With Our PatientsHow pharmacists can use shared decision-making to improve antibiotic use.
Latest:
Respiratory Syncytial Viral Infection: Treatment With Ziresovir in InfantsFindings from a recent phase 3 trial show promising results for the approval of ziresovir in the treatment of respiratory syncytial virus in infants.
Latest:
A Day Late and a Dollar Short: Managing Antimicrobial Drug ShortagesWith antimicrobial drug shortages expected to continue globally, developing mitigation strategies is essential to prevent complications, including antimicrobial resistance.
Latest:
Practice Pearls for Treatment of Respiratory InfectionsTina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
Latest:
Multidisciplinary Perspectives on HIV TreatmentA multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
